<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523584</url>
  </required_header>
  <id_info>
    <org_study_id>CIN_US Liver Fat</org_study_id>
    <nct_id>NCT04523584</nct_id>
  </id_info>
  <brief_title>Ultrasound Quantification of Liver Fat</brief_title>
  <official_title>Ultrasound Quantification of Liver Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siemens Medical Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan a prospective study designed to evaluate the accuracy of a new&#xD;
      ultrasound method for quantification of liver fat content.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MRI proton density fat fraction (PDFF) will serve as the reference standard for liver fat&#xD;
      fraction measurements. The strength of agreement between ultrasound derived fat fraction&#xD;
      (UDFF) and PDFF will be the outcome of interest for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2020</start_date>
  <completion_date type="Anticipated">February 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 14, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MRI PDFF correlation/agreement to UDFF</measure>
    <time_frame>Single time point-30 minute MRI/30 minute Ultrasound</time_frame>
    <description>Liver fat % derived using MR PDFF will be compared to UDFF</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Hepatic Steatosis</arm_group_label>
    <description>&lt;5% liver fat fraction by MRI PDFF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Hepatic Steatosis</arm_group_label>
    <description>&gt;5% liver fat fraction by MRI PDFF</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>Participants will undergo MR imaging of the liver. Liver PDFF will be measured.</description>
    <arm_group_label>Hepatic Steatosis</arm_group_label>
    <arm_group_label>No Hepatic Steatosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound Imaging</intervention_name>
    <description>Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.</description>
    <arm_group_label>Hepatic Steatosis</arm_group_label>
    <arm_group_label>No Hepatic Steatosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 16 years of age or older with known fatty liver disease (based upon prior MRI or&#xD;
        ultrasound), or at risk for fatty liver disease (obese).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 16 years of age or older with known fatty liver disease (based upon prior MRI&#xD;
             or ultrasound), or at risk for fatty liver disease (obese).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject under the age of 16&#xD;
&#xD;
          -  Pregnant subject&#xD;
&#xD;
          -  Subjects who cannot cooperate with performance of the ultrasound exam&#xD;
&#xD;
          -  Subjects who cannot cooperate with performance of the MRI exam&#xD;
&#xD;
          -  Subjects who have contraindications to MRI&#xD;
&#xD;
          -  Subjects who might require sedation or anesthesia to undergo study imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Trout, MD</last_name>
    <phone>513-803-3004</phone>
    <email>andrew.trout@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Dillman, MD, MSc</last_name>
    <phone>513-803-7114</phone>
    <email>jonathan.dillman@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Trout, MD</last_name>
      <phone>513-803-3004</phone>
      <email>andrew.trout@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Dillman, MD, MSc</last_name>
      <phone>513-803-7114</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hanquinet S, Rougemont AL, Courvoisier D, Rubbia-Brandt L, McLin V, Tempia M, Anooshiravani M. Acoustic radiation force impulse (ARFI) elastography for the noninvasive diagnosis of liver fibrosis in children. Pediatr Radiol. 2013 Mar;43(5):545-51. doi: 10.1007/s00247-012-2595-8. Epub 2012 Dec 28.</citation>
    <PMID>23271404</PMID>
  </reference>
  <reference>
    <citation>Fierbinteanu Braticevici C, Sporea I, Panaitescu E, Tribus L. Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease. Ultrasound Med Biol. 2013 Nov;39(11):1942-50. doi: 10.1016/j.ultrasmedbio.2013.04.019. Epub 2013 Aug 9.</citation>
    <PMID>23932277</PMID>
  </reference>
  <reference>
    <citation>Kinner S, Reeder SB, Yokoo T. Quantitative Imaging Biomarkers of NAFLD. Dig Dis Sci. 2016 May;61(5):1337-47. doi: 10.1007/s10620-016-4037-1. Epub 2016 Feb 5. Review.</citation>
    <PMID>26848588</PMID>
  </reference>
  <reference>
    <citation>Middleton MS, Van Natta ML, Heba ER, Alazraki A, Trout AT, Masand P, Brunt EM, Kleiner DE, Doo E, Tonascia J, Lavine JE, Shen W, Hamilton G, Schwimmer JB, Sirlin CB; NASH Clinical Research Network. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology. 2018 Mar;67(3):858-872. doi: 10.1002/hep.29596. Epub 2018 Jan 26.</citation>
    <PMID>29028128</PMID>
  </reference>
  <reference>
    <citation>Trout AT, Dillman JR, Xanthakos S, Kohli R, Sprague G, Serai S, Mahley AD, Podberesky DJ. Prospective Assessment of Correlation between US Acoustic Radiation Force Impulse and MR Elastography in a Pediatric Population: Dispersion of US Shear-Wave Speed Measurement Matters. Radiology. 2016 Nov;281(2):544-552. Epub 2016 May 26.</citation>
    <PMID>27228332</PMID>
  </reference>
  <reference>
    <citation>Tyagi A, Yeganeh O, Levin Y, Hooker JC, Hamilton GC, Wolfson T, Gamst A, Zand AK, Heba E, Loomba R, Schwimmer J, Middleton MS, Sirlin CB. Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults. Abdom Imaging. 2015 Oct;40(8):3070-7. doi: 10.1007/s00261-015-0542-5.</citation>
    <PMID>26350282</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

